Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.
Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.
Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.
Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.
Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.
For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.
Exelixis, Inc. (NASDAQ: EXEL) released initial results from the QUARTZ-101 trial, evaluating XL102, a CDK7 inhibitor for advanced solid tumors. The trial shows XL102 was well tolerated across five dose levels with 26 patients treated. Most common cancer types included hormone receptor-positive breast cancer, pancreatic cancer, and sarcoma. Although no objective responses were observed, two patients showed stable disease. The ongoing study will assess the safety and efficacy of XL102, with further evaluations planned in combination therapies.
Exelixis, Inc. (Nasdaq: EXEL) will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 12:00 pm ET. Access the webcast at www.exelixis.com. A replay will be available for 30 days.
Exelixis focuses on oncology, offering products like CABOMETYX®, COMETRIQ®, and COTELLIC®. The company aims to develop new therapies for challenging cancers, leveraging its established drug discovery platform.
Exelixis (Nasdaq: EXEL) announced management's participation in several investor conferences in November. Key presentations include: Stifel Healthcare Conference in New York on November 16, Jefferies London Healthcare Conference also on November 16, and Piper Sandler's Healthcare Conference in New York on November 29. Additionally, Exelixis will present virtually at the Evercore ISI HealthCONx on November 29. Webcast access and replays will be available on www.exelixis.com.
Exelixis (Nasdaq: EXEL) has entered a new licensing agreement with Catalent (NYSE: CTLT) for three oncology programs aimed at developing antibody-drug conjugates (ADCs) for various solid tumors. Exelixis will pay $30 million upfront for rights to the biologics programs and will fund the development until candidate selection. This collaboration enhances Exelixis’ biologics pipeline, targeting cancers including bladder, breast, and ovarian. Catalent's SMARTag technology will support the development, potentially improving treatment options for cancer patients.
Exelixis has entered into an exclusive agreement with Sairopa for the clinical development of ADU-1805, a monoclonal antibody targeting SIRPα, expected to improve immune response against tumors. An IND filing is anticipated in Q1 2023, which could expand Exelixis' clinical pipeline. The agreement includes a $40 million upfront payment and potential milestone payments totaling $70 million. ADU-1805 shows promise against multiple tumor types and might have a better safety profile than existing therapies.
Exelixis has formed an exclusive collaboration with Cybrexa Therapeutics to acquire CBX-12, a novel peptide-drug conjugate designed to enhance cancer treatment efficacy while reducing toxicity. The collaboration underscores Exelixis' commitment to expanding its clinical pipeline. Exelixis will pay an upfront fee of $60 million plus potential milestone payments up to $642.5 million. Initial data from a Phase 1 trial of CBX-12 indicate promising anti-tumor activity, including complete response in a patient with ovarian cancer, highlighting its potential in treating diverse tumors.
Exelixis reported Q3 2022 total revenues of $411.7 million, a 25% year-over-year increase, driven mainly by cabozantinib franchise revenues of $366.5 million, which showed 39% growth year-over-year. GAAP diluted EPS was $0.23, and non-GAAP diluted EPS was $0.31. R&D expenses rose to $198.8 million due to increased clinical trial costs. The company provided updated 2022 financial guidance, expecting total revenues between $1.575 billion and $1.600 billion, with net product revenues of $1.375 billion to $1.400 billion.
Exelixis announced initial results from the JEWEL-101 phase 1 study of XB002, a next-generation tissue factor-targeting antibody-drug conjugate. Presented at a recent symposium, XB002 was well-tolerated, with pharmacokinetic analysis indicating stability and low free payload levels. A total of 19 patients were enrolled at escalating doses, with no dose-limiting toxicities reported. The study aims to evaluate XB002's efficacy in patients with advanced solid tumors, with a particular focus on those with limited treatment options.
Exelixis, Inc. (Nasdaq: EXEL) will release its third quarter 2022 financial results on
Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is Exelixis Inc. known for?
What are the main products of Exelixis?
When was Cometriq first approved?
Who are the key partners of Exelixis?
What type of cancer is Cometriq used to treat?
What is Cabometyx used for?
Where can I find job opportunities at Exelixis?
How has the financial performance of Exelixis been?
What kind of research does Exelixis focus on?
What is the ticker symbol for Exelixis Inc.?
